• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Abbott touts study showing SCS helps curb opioid use in chronic pain patients

January 23, 2017 By Sarah Faulkner

Abbott touts study showing SCS helps curb opioid use in chronic pain patientsAbbott (NYSE:ABT) touted data from a 5,400 patient study evaluating daily opioid use following spinal cord stimulation therapy in patients with chronic pain. The researchers found that average daily opioid use declined or remained steady for patients with a spinal cord stimulation system compared to patient use of opioids prior to the implant.

Patients who had the spinal cord stim implant removed experienced greater opioid use over time, the company reported. In a spinal cord stimulation system, a device similar to a pacemaker is implanted in the patient’s spinal cord and delivers low levels of electrical energy to nerve fibers. The energy disrupts pain signals as they travel to the brain, reducing the sensation of pain.

The Abbott-sponsored study demonstrated that 1 year after implantation, 93% of patients who continued spinal cord stimulation therapy had lower average daily morphine-equivalent doses than patients who had their implant removed.

“Given the epidemic of opioid addiction and abuse, these findings are important and confirm that spinal cord stimulation therapy can offer strong benefits for patients struggling with chronic pain,” Dr. Ashwini Sharan, president of the North American Neuromodulation Society, said in prepared remarks. “Based on these results, we concluded it may be possible to improve outcomes by offering our patients spinal cord stimulation earlier, before opioid dependence and addiction can occur.”

Last week, Abbott launched its Proclaim dorsal root ganglion neurostimulation system in Europe for patients suffering from chronic neuropathic pain.

The Abbott Park, Il.-based company’s system targets sensory nerves packed within the dorsal root ganglion to directly target the area of the body where pain occurs and provide stronger pain relief compared to traditional spinal cord stimulation therapy.

Abbott claims it is the only company to offer a neurostim device designed for DRG therapy. Patients with chronic neuropathic pain can access the company’s Proclaim platform and an iPod touch mobile digital device patient controller that features wireless communication via Bluetooth.

Filed Under: Featured, Implants, Pain Management, Wall Street Beat Tagged With: Abbott Laboratories

IN CASE YOU MISSED IT

  • Embecta stock soars on first full-quarter results after BD spinoff
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling
  • Senseonics stock is up as it sticks by revenue guidance

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS